How did you prepare for the use of Dexter?
Matthaei: At first, we only got to know the system theoretically, then we followed a dry lab training of several months on the system and simulators in our center. In between, we were able to train at training centers in Switzerland and France on body donations, among other things. Only recently we performed our first operation.
Arensmeyer: In all our project activities, we always keep patient safety in mind as a key aspect, because technology is extremely dynamic at the moment. This applies not only to robotics, but also to the integration of AI-supported decision-making aids and augmented realities.
All of these combined will present us with very exciting but also challenging changes. Therefore, as a surgical team, we have given a lot of thought to how we can implement technologies with maximum patient safety and also sustainability. To some extent, this also goes beyond the expertise of the surgical community, which is why we have networked with partners from ethics and law both within and outside the university.
How and when would you use on-demand robotics in the future?
Matthaei: In principle, on-demand robotics can be used for all operations that would otherwise be minimally invasive. Of course, this procedure is particularly advantageous for complex surgical steps, where experience has shown that we benefit from the advantages of robotics – for example, when high magnification, 3D visualization and fine, tremor-free preparation of structures are required. Due to its simplicity, Dexter is also particularly suitable for surgical teaching and training.
Since this system can also be used to perform less complex operations efficiently, for example gall bladder removals or inguinal hernia closures, young surgeons can also be introduced to the topic of robotics in an uncomplicated manner. It is advantageous to sensitize doctors to the topic of "digital surgery" as early as possible and to get them excited about it, as this is without question the future.
We also see enormous potential for research and development in very different areas in the coming decades, which, in addition to patients, could be extremely beneficial to Germany/Europe as a business location if we are involved at an early stage.